anthralin has been researched along with Hyperplasia in 8 studies
Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.
anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
Excerpt | Relevance | Reference |
---|---|---|
" Although dose-response comparisons indicated that chrysarobin was several orders of magnitude less potent than TPA for promoting papilloma formation, this anthrone was 1." | 1.27 | Mechanism of mouse skin tumor promotion by chrysarobin. ( Aalfs, KK; Cantor, J; Coombs, MM; Decina, PC; DiGiovanni, J; Prichett, WP, 1985) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (62.50) | 18.7374 |
1990's | 3 (37.50) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Klein-Szanto, AJ | 2 |
Major, SK | 1 |
Slaga, TJ | 2 |
La, E | 1 |
Muga, SJ | 1 |
Locniskar, MF | 1 |
Fischer, SM | 1 |
Viluksela, M | 2 |
Kosma, VM | 3 |
Männistö, PT | 1 |
Hanhijärvi, H | 1 |
Collan, Y | 2 |
Naukkarinen, A | 1 |
Aalto, ML | 1 |
Männistö, P | 1 |
DiGiovanni, J | 1 |
Decina, PC | 1 |
Prichett, WP | 1 |
Cantor, J | 1 |
Aalfs, KK | 1 |
Coombs, MM | 1 |
8 other studies available for anthralin and Hyperplasia
Article | Year |
---|---|
Quantitative evaluation of dark keratinocytes induced by several promoting and hyperplasiogenic agents: their use as an early morphological indicator of tumor-promoting action.
Topics: Alkynes; Anthralin; Calcimycin; Carcinogens; Diterpenes; Epidermal Cells; Epidermis; Hyperplasia; Ke | 1982 |
Numerical variation of dark cells in normal and chemically induced hyperplastic epidermis with age of animal and efficiency of tumor promoter.
Topics: Administration, Topical; Age Factors; Alkynes; Animals; Anthralin; Calcimycin; Carcinogens; Epidermi | 1981 |
Altered expression of interleukin-1 receptor antagonist in different stages of mouse skin carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anthralin; Blotting, Northern; Blotting, Western; Carcino | 1999 |
Dithranol (anthralin)-induced skin irritation in C57BL/6, NMRI and SENCAR mice.
Topics: Animals; Anthralin; Dermatitis, Contact; Dose-Response Relationship, Drug; Edema; Female; Hyperplasi | 1991 |
Characteristics and modulation of dithranol (anthralin)-induced skin irritation in the mouse ear model.
Topics: Administration, Topical; Adrenal Cortex Hormones; Animals; Anthralin; Anti-Inflammatory Agents, Non- | 1991 |
A 6-month dermal toxicity test with dithranol and butantrone in miniature swine.
Topics: Administration, Topical; Animals; Anthralin; Drug Eruptions; Drug Evaluation, Preclinical; Female; G | 1986 |
Histopathological and morphometrical analysis applied to skin changes in NMRI mice induced by dithranol (anthranil) and its acyl analogs.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anthralin; Cell Nucleus; DNA; Female; Hyperplasia; Mice; | 1986 |
Mechanism of mouse skin tumor promotion by chrysarobin.
Topics: Animals; Anthracenes; Anthralin; Carcinogens; Dose-Response Relationship, Drug; Edema; Female; Hyper | 1985 |